Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation
PHASE2CompletedINTERVENTIONAL
Enrollment
50
Participants
Timeline
Start Date
May 31, 1999
Study Completion Date
April 30, 2000
Conditions
Kidney Transplantation
Interventions
DRUG
BG9588
Trial Locations (1)
20892
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda
All Listed Sponsors
lead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
NCT00001857 - Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation | Biotech Hunter | Biotech Hunter